Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZLI 14-day versus 28-day treatment for new-onset Pseudomonas aeruginosa infection in pediatric cystic fibrosis
2016-002749-42Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2017
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aztreonam in Pseudomonas aeruginosa airway infection and cystic fibrosis (CF) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Pseudomonas aeruginosa eradication over 28-day post-treatment follow-up. Started Jul 2017; status: completed.
02
Drugs
aztreonam
03
Conditions
Pseudomonas aeruginosa airway infectioncystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-002749-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002749-42.